| Literature DB >> 30624183 |
Jack Khouri1, Christy Samaras2,3, Jason Valent2,3, Alex Mejia Garcia2, Beth Faiman4, Saveta Mathur2, Kimberly Hamilton2, Megan Nakashima5,6, Matt Kalaycio7,8,9.
Abstract
Monoclonal gammopathy of undetermined significance (MGUS) is commonly diagnosed in outpatients being worked up for an array of clinical concerns. It carries a risk of progression to myeloma and other lymphoproliferative disorders that, albeit low (1% per year), warrants regular follow-up. Patients with MGUS can be risk-stratified on the basis of the amount and type of their monoclonal protein as well as whether they have an abnormal light-chain ratio. Here, we provide a guide to the diagnosis, workup, and management of MGUS.Entities:
Year: 2019 PMID: 30624183 DOI: 10.3949/ccjm.86a.17133
Source DB: PubMed Journal: Cleve Clin J Med ISSN: 0891-1150 Impact factor: 2.321